-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

322.O1.6 322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term

Symposia: Hemophilia A and B: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Antibody Therapy, Adult, Hemophilia, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Clinical Research, Pediatric, Diseases, Patient-reported outcomes, Treatment Considerations, Biological therapies, Immunology, Monoclonal Antibody Therapy, Biological Processes, Study Population, Human
Monday, December 9, 2024: 10:30 AM-12:00 PM
Room 30 (San Diego Convention Center)
Moderators:
Johnny Mahlangu, MD, and Allison P. Wheeler, MD, ARRAY(0xf80f3f8)
Disclosures:
Wheeler: Novo Nordisk: Consultancy, Honoraria, Research Funding; Octapharma: Research Funding; Bayer: Honoraria; BioMarin: Honoraria; Bioverativ: Honoraria; CSL Behring: Honoraria; Genentech: Honoraria; HEMA Biologics: Honoraria; Octapharma USA: Honoraria; Pfizer Inc: Honoraria; Sanofi-Aventis USA: Honoraria; Shire North America: Honoraria; Spark Therapeutics: Honoraria; Takeda Pharmaceuticals: Honoraria.
This session will present the latest data on safety and efficacy of diverse novel hemostatic agents used for the prevention of bleeds in hemophilia A and B with and with inhibitors. The data on pediatric patients and long term effects of these therapies will be included.
10:30 AM

Amy D. Shapiro, MD1, Shashikant Apte2, Ana Boban3*, Renée Brown Frandsen4*, Silvia Linari5*, Johnny Mahlangu, MD6, Camila Martins Mazini Tavares4*, Tadashi Matsushita, MD7, Salim Nekkal8*, Jameela Sathar9* and Anthony K C Chan10

1Indiana Hemophilia & Thrombosis Center, Indianapolis, IN
2Sahyadri Specialty Hospital, Pune, India
3Haemophilia Centre, Department of Haematology, University Hospital Centre Zagreb, Zagreb University School of Medicine, Zagreb, Croatia
4Novo Nordisk A/S, Søborg, Denmark
5Center for Bleeding Disorders and Coagulation, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
6Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
7Nagoya University Hospital, Nagoya, Japan
8Blood Transfusion Center, University Hospital Medical Center Beni Messous, Algiers, Algeria
9Department of Hematology, Ampang Hospital, Kuala Lumpur, Malaysia
10McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada

10:45 AM

Davide Matino, MD, MSc1*, Travis Gould, PhD2, John Teeter, MD3*, Carrie Turich Taylor, PhD, MHS3*, Regina McDonald, BSN2* and Andrew Palladino, MD4*

1McMaster University, Hamilton, ON, Canada
2Pfizer Inc, New York, NY
3Pfizer Inc, Groton, CT
4Global Clinical Lead for the Marstacimab Program at Pfizer, Pfizer Inc, Collegeville, PA

11:00 AM

Robert Klamroth, MD1*, Stephanie P'ng2*, Sophie Susen3*, Davide Matino, MD, MSc4*, Pratima Chowdary5*, Angela C Weyand, MD6, Toshko Lissitchkov7*, Young-Shil Park8*, María Teresa Alvarez-Román, PhD, MD9*, Liqi Feng10*, Helena Palmborg11*, Jennifer Dumont12, Elena Santagostino13, Lara Mamikonian12* and Keiji Nogami14*

1Vivantes Klinikum, Friedrichshain, Berlin, Germany
2The Haemophilia and Haemostasis Centre, Fiona Stanley Hospital, Murdoch, Australia
3Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
4Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Ontario, Canada
5Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom
6Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI
7Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria
8Department of Pediatrics, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, Korea, Republic of (South)
9Department of Hematology, University Hospital La Paz, Autonoma University of Madrid, Madrid, Spain
10Sanofi, Shanghai, China
11Sobi, Stockholm, Sweden
12Sanofi, Cambridge, MA
13Sobi, Basel, Switzerland
14Nara Medical University, Nara, Japan

11:15 AM

Tadashi Matsushita, MD1, Pratima Chowdary, MD, MRCP, FRCPath2*, Atanas Mitkov Banchev, MD, PhD3*, Kaan Kavakli4*, Johanna A. Kremer Hovinga, MD5, Jerzy Windyga, MD, PhD6, Víctor Jiménez-Yuste, MD, PhD7*, Julien Bovet8*, Llenalia María García Fernández9* and Guy Young, MD10

1Nagoya University Hospital, Nagoya, Japan
2Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom
3Paediatric Haematology and Oncology Department, University Hospital Tsaritsa Giovanna – ISUL, Sofia, Bulgaria
4Department of Pediatric Hematology, Ege University Children’s Hospital, Izmir, Turkey
5Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern, Switzerland
6Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
7Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain
8Novo Nordisk, Paris, France
9Novo Nordisk, Madrid, Spain
10Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA

11:30 AM

Christoph Königs1*, Doris V. Quon, MD, PhD2, Cedric Hermans, MD, MRCP, PhD3, Nana Kragh, MSc4*, Jérôme Msihid, MSc5*, Emilie Gerard5*, Duygu Bozkaya6*, Linda Bystrická7*, Cecile Le Camus6*, Elena Santagostino8, Annemieke Willemze, MD9 and Annette von Drygalski, MD, PharmD, RMSK10

1University Hospital Frankfurt, Goethe University, Frankfurt, Germany
2Orthopaedic Institute for Children, Orthopaedic Hemophilia Treatment Center, Los Angeles, CA
3Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
4Sobi, Stockholm, Sweden
5Sanofi, Gentilly, France
6Sanofi, Cambridge, MA
7Swedish Orphan Biovitrum AB, Stockholm, Sweden
8Sobi, Basel, Switzerland
9Sanofi, Amsterdam, NLD
10Center for Bleeding and Clotting Disorders, University of California San Diego, San Diego, CA

11:45 AM

Jessica O. Frade-Guanaes, MSc1*, Carolina Costa-Lima, MD1,2*, Vanessa B. Faiotto, MSc1*, Ana P. Francisco1*, Nívia M. Foschi, MD1*, Andrea L. A. Sambo, RN1*, Mariana M. T. Hosokawa, RN1*, Valdirene Stahl, RN1*, Luiz G. R. Lima1*, Bianca Stefanello1*, Lucas W. Weiss Santos, MD1*, Samuel S. Medina, MD1*, Marina P. Colella, MD, PhD1*, Silmara A. De Lima Montalvão, PhD1*, Gabriela G. Yamaguti-Hayakawa1* and Margareth C. Ozelo, MD, PhD1,2

1Hemocentro UNICAMP, University of Campinas, Campinas, SP, Brazil
2Department of Internal Medicine, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, SP, Brazil

*signifies non-member of ASH